All PROs significantly higher for those discontinuing TNFi at week 12 vs week 0, but not at later time points.

HealthDay News — For patients with atrial fibrillation (AF) and prior intracranial bleeding, direct oral anticoagulants (DOACs) are associated with a reduced risk for ischemic stroke (IS) and death, ...

Interim data from the open-label phase 3 MagnetisMM-32 study demonstrate a significant progression free survival benefit with elranatamab monotherapy vs active standard regimens in patients previously ...

Topline phase 3 data show tradipitant significantly reduced semaglutide-associated vomiting and severe nausea in adults with ...

HealthDay News — For patients with moderately to severely active ulcerative colitis, oral icotrokinra, a peptide that blocks the interleukin-23 receptor, yields a clinical response at week 12 ...

HealthDay News — Treating depression with interpersonal psychotherapy during pregnancy influences infant brain development ...

HealthDay News — Early uptake was rapid for oral semaglutide (Wegovy pill) relative to injectable incretin-based weight ...

Adults with moderately to severely active Crohn disease can now self-administer risankizumab induction at home using an ...

HealthDay News — Medical device adverse event reports are frequently incomplete, inaccurate, and delayed, according to a study published online October 14 in The BMJ.

The investigational vaccine targets pathological amyloid-beta to lower brain amyloid in patients with preclinical Alzheimer ...

The new 150mg oral pellet formulation provides a capsule-free prophylactic option for adults and adolescents with hereditary ...

Patients with baseline viral suppression maintained viral suppression, while those without achieved viral suppression by 13 ...